Related Experiment Videos
[Clinical studies on TMS-19-Q.O tablet in respiratory tract infection]
Abstract:
A new macrolide antibiotic preparation, TMS-19-Q.O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: Three hundred and seven cases were included in this report, and overall efficacy rate was 76.2%. Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.
Insights
A new macrolide antibiotic, TMS-19-Q.O tablet, showed 76.2% efficacy for respiratory tract infections, particularly pneumonia. The optimal dose for this antibiotic was determined to be 600 mg.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Respiratory tract infections (RTIs) pose a significant global health burden.
- Macrolide antibiotics are crucial for treating bacterial RTIs.
- Novel macrolide preparations require rigorous efficacy and safety evaluation.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of TMS-19-Q.O tablet in patients with RTIs.
- To determine the optimal dosage of TMS-19-Q.O for treating RTIs.
- To assess the bacteriological effectiveness against common respiratory pathogens.
Main Methods:
- A clinical trial involving 307 patients with RTIs.
- Assessment of overall clinical efficacy and specific effects on pneumonia.
- Evaluation of bacteriological response against Gram-positive cocci and Gram-negative rods.
- Monitoring of adverse events and laboratory abnormalities.
Main Results:
- Overall efficacy rate was 76.2%.
- High clinical effectiveness (86.0%) observed in pneumonia, including mycoplasmal pneumonia.
- Bacteriological efficacy: 87.5% for Gram-positive cocci, 48.0% for Gram-negative rods.
- Low incidence of side effects (3.50%) and laboratory abnormalities (7.5%).
Conclusions:
- TMS-19-Q.O tablet demonstrates significant efficacy in treating respiratory tract infections, especially pneumonia.
- A dosage of 600 mg is recommended for optimal clinical and bacteriological outcomes.
- The antibiotic exhibits a favorable safety profile with minimal adverse effects.